Generation Bio is a genetic medicines company creating gene therapy utilizing its non-viral gene therapy platform. It combines three technologies: a cell-targeted lipid nanoparticle delivery system (ctLNP), a closed-ended DNA construct (ceDNA), and a high-capacity capsid-free biologics manufacturing process. In addition to its lead liver-targeted programs in hemophilia A and phenylketonuria (PKU), Generation Bio develops gene therapies for patients with diseases of skeletal muscle and the eye.
|HQ||Cambridge, MA, US||Map|
Net income (FY, 2020)
EBIT (FY, 2020)
Market capitalization (15-Jul-2021)
Closing stock price (15-Jul-2021)
Generation Bio has 2 Twitter Followers.
When was Generation Bio founded?
Generation Bio was founded in 2016.
Who are Generation Bio key executives?
Generation Bio's key executives are Stephen Dipalma, Doug Kerr and Matthew Stanton.
How many employees does Generation Bio have?
Generation Bio has 85 employees.
Who are Generation Bio competitors?
Competitors of Generation Bio include XBiotech, Neuren Pharmaceuticals and GeneQuine Biotherapeutics.
Where is Generation Bio headquarters?
Generation Bio headquarters is located at 301 Binney St, Cambridge.
Where are Generation Bio offices?
Generation Bio has an office in Cambridge.
How many offices does Generation Bio have?
Generation Bio has 1 office.
Receive alerts for 300+ data fields across thousands of companies